PTC Therapeutics Inc
PTCT52.345USD
+0.215+0.41%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
4.15BCap. mercado
6.97P/E TTM
Más Datos de PTC Therapeutics Inc Compañía
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company has a diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Información de la empresa
Símbolo de cotizaciónPTCT
Nombre de la empresaPTC Therapeutics Inc
Fecha de salida a bolsaJun 20, 2013
Director ejecutivoDr. Matthew B. Klein, M.D.
Número de empleados939
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 20
Dirección500 Warren Corporate Center Drive
CiudadWARREN
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal07059
Teléfono19082227000
Sitio Webhttps://www.ptcbio.com/
Símbolo de cotizaciónPTCT
Fecha de salida a bolsaJun 20, 2013
Director ejecutivoDr. Matthew B. Klein, M.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Michael Schmertzler
Mr. Michael Schmertzler
Independent Chairman of the Board
Independent Chairman of the Board
126.60K
+0.53%
Dr. Matthew B. Klein, M.D.
Dr. Matthew B. Klein, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
87.68K
-13.92%
Mr. Mark Elliott Boulding
Mr. Mark Elliott Boulding
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
60.20K
--
Ms. Christine Marie Utter
Ms. Christine Marie Utter
Senior Vice President, Chief Accounting Officer, Head - People Services
Senior Vice President, Chief Accounting Officer, Head - People Services
54.45K
-3.13%
Mr. Eric Pauwels
Mr. Eric Pauwels
Chief Business Officer
Chief Business Officer
19.79K
-16.96%
Mr. Pierre Gravier
Mr. Pierre Gravier
Chief Financial Officer
Chief Financial Officer
18.36K
-12.05%
Mr. David P. Southwell
Mr. David P. Southwell
Independent Director
Independent Director
16.17K
+13.98%
Dr. Jerome B. Zeldis, M.D., Ph.D.
Dr. Jerome B. Zeldis, M.D., Ph.D.
Independent Director
Independent Director
16.17K
+2.10%
Ms. Emma Reeve
Ms. Emma Reeve
Independent Director
Independent Director
12.87K
+2.66%
Ms. Stephanie S. Okey
Ms. Stephanie S. Okey
Independent Director
Independent Director
6.53K
+5.37%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Michael Schmertzler
Mr. Michael Schmertzler
Independent Chairman of the Board
Independent Chairman of the Board
126.60K
+0.53%
Dr. Matthew B. Klein, M.D.
Dr. Matthew B. Klein, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
87.68K
-13.92%
Mr. Mark Elliott Boulding
Mr. Mark Elliott Boulding
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
60.20K
--
Ms. Christine Marie Utter
Ms. Christine Marie Utter
Senior Vice President, Chief Accounting Officer, Head - People Services
Senior Vice President, Chief Accounting Officer, Head - People Services
54.45K
-3.13%
Mr. Eric Pauwels
Mr. Eric Pauwels
Chief Business Officer
Chief Business Officer
19.79K
-16.96%
Mr. Pierre Gravier
Mr. Pierre Gravier
Chief Financial Officer
Chief Financial Officer
18.36K
-12.05%
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
413.04M
51.20%
Non-US
393.74M
48.80%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 16 de may
Actualizado: vie., 16 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
10.84%
RTW Investments L.P.
9.44%
BlackRock Institutional Trust Company, N.A.
7.50%
Armistice Capital LLC
6.86%
Wellington Management Company, LLP
6.84%
Other
58.52%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
10.84%
RTW Investments L.P.
9.44%
BlackRock Institutional Trust Company, N.A.
7.50%
Armistice Capital LLC
6.86%
Wellington Management Company, LLP
6.84%
Other
58.52%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
40.10%
Investment Advisor
34.56%
Hedge Fund
20.09%
Research Firm
5.93%
Corporation
1.75%
Venture Capital
0.78%
Pension Fund
0.74%
Individual Investor
0.71%
Bank and Trust
0.31%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
542
83.25M
105.04%
-7.03M
2025Q1
551
82.28M
103.88%
-8.58M
2024Q4
513
80.63M
102.26%
-7.88M
2024Q3
503
82.04M
106.59%
-9.34M
2024Q2
498
82.97M
107.86%
-13.36M
2024Q1
493
89.17M
116.42%
-6.48M
2023Q4
485
88.17M
116.52%
-2.91M
2023Q3
477
85.04M
112.75%
-2.96M
2023Q2
478
84.63M
112.42%
-161.84K
2023Q1
486
82.00M
110.89%
-2.44M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
8.59M
10.84%
-571.45K
-6.24%
Mar 31, 2025
RTW Investments L.P.
7.48M
9.44%
+90.00K
+1.22%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.95M
7.5%
-111.10K
-1.83%
Mar 31, 2025
Armistice Capital LLC
5.43M
6.86%
-943.16K
-14.79%
Mar 31, 2025
Wellington Management Company, LLP
5.42M
6.84%
+632.05K
+13.20%
Mar 31, 2025
Janus Henderson Investors
2.92M
3.68%
+590.81K
+25.40%
Mar 31, 2025
TD Securities, Inc.
2.61M
3.3%
-673.53K
-20.49%
Mar 31, 2025
State Street Global Advisors (US)
2.45M
3.1%
-253.10K
-9.35%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.87M
2.36%
+76.87K
+4.28%
Mar 31, 2025
Driehaus Capital Management, LLC
1.51M
1.91%
+471.59K
+45.30%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Neuroscience and Healthcare ETF
4.12%
Invesco Biotechnology & Genome ETF
2.71%
ALPS Medical Breakthroughs ETF
2.62%
Virtus LifeSci Biotech Products ETF
1.85%
Harbor Human Capital Factor US Small Cap ETF
1.71%
Tema Neuroscience and Mental Health ETF
1.56%
Invesco Dorsey Wright Healthcare Momentum ETF
1.38%
Global X Guru Index ETF
1.29%
SPDR S&P Biotech ETF
1.21%
VictoryShares Small Cap Free Cash Flow ETF
0.88%
Ver más
iShares Neuroscience and Healthcare ETF
Proporción4.12%
Invesco Biotechnology & Genome ETF
Proporción2.71%
ALPS Medical Breakthroughs ETF
Proporción2.62%
Virtus LifeSci Biotech Products ETF
Proporción1.85%
Harbor Human Capital Factor US Small Cap ETF
Proporción1.71%
Tema Neuroscience and Mental Health ETF
Proporción1.56%
Invesco Dorsey Wright Healthcare Momentum ETF
Proporción1.38%
Global X Guru Index ETF
Proporción1.29%
SPDR S&P Biotech ETF
Proporción1.21%
VictoryShares Small Cap Free Cash Flow ETF
Proporción0.88%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
